Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines.

White MT, Griffin JT, Riley EM, Drakeley CJ, Moorman AM, Sumba PO, Kazura JW, Ghani AC, John CC.

Proc Biol Sci. 2011 May 7;278(1710):1298-305. doi: 10.1098/rspb.2010.1697. Epub 2010 Oct 13.

2.

Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection.

John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, Lanar DE, Schluchter MD, Kazura JW.

Am J Trop Med Hyg. 2005 Jul;73(1):222-8.

PMID:
16014863
3.

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.

White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC.

Lancet Infect Dis. 2015 Dec;15(12):1450-8. doi: 10.1016/S1473-3099(15)00239-X. Epub 2015 Sep 2.

4.

Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, Kazura JW.

J Infect Dis. 2008 Feb 15;197(4):519-26. doi: 10.1086/526787.

5.

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.

Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA.

Vaccine. 2010 Oct 21;28(45):7256-66. doi: 10.1016/j.vaccine.2010.08.098. Epub 2010 Sep 21.

6.

IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.

Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, Crisanti A, Wightman PD, Ockenhouse CF, Dutta S.

PLoS One. 2014 Oct 24;9(10):e111020. doi: 10.1371/journal.pone.0111020. eCollection 2014.

7.

Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.

Kester KE, Gray Heppner D Jr, Moris P, Ofori-Anyinam O, Krzych U, Tornieporth N, McKinney D, Delchambre M, Ockenhouse CF, Voss G, Holland C, Beckey JP, Ballou WR, Cohen J; RTS,S/TRAP Group.

Vaccine. 2014 Nov 20;32(49):6683-91. doi: 10.1016/j.vaccine.2014.06.033. Epub 2014 Jun 18.

8.

Tailoring a Combination Preerythrocytic Malaria Vaccine.

Bauza K, Atcheson E, Malinauskas T, Blagborough AM, Reyes-Sandoval A.

Infect Immun. 2015 Dec 14;84(3):622-34. doi: 10.1128/IAI.01063-15.

9.

The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.

White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC.

PLoS One. 2013 Apr 16;8(4):e61395. doi: 10.1371/journal.pone.0061395. Print 2013.

10.

Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis.

Felgner PL, Roestenberg M, Liang L, Hung C, Jain A, Pablo J, Nakajima-Sasaki R, Molina D, Teelen K, Hermsen CC, Sauerwein R.

Sci Rep. 2013 Dec 19;3:3549. doi: 10.1038/srep03549. Erratum in: Sci Rep. 2014;4:4151.

11.

Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum.

Clement F, Dewar V, Van Braeckel E, Desombere I, Dewerchin M, Swysen C, Demoitié MA, Jongert E, Cohen J, Leroux-Roels G, Cambron P.

Malar J. 2012 Nov 22;11:384. doi: 10.1186/1475-2875-11-384.

12.

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.

Foquet L, Hermsen CC, van Gemert GJ, Van Braeckel E, Weening KE, Sauerwein R, Meuleman P, Leroux-Roels G.

J Clin Invest. 2014 Jan;124(1):140-4.

13.

Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development.

Aguiar JC, Bolton J, Wanga J, Sacci JB, Iriko H, Mazeika JK, Han ET, Limbach K, Patterson NB, Sedegah M, Cruz AM, Tsuboi T, Hoffman SL, Carucci D, Hollingdale MR, Villasante ED, Richie TL.

PLoS One. 2015 Aug 20;10(8):e0136109. doi: 10.1371/journal.pone.0136109. eCollection 2015.

14.

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Pichyangkul S, Kum-Arb U, Yongvanitchit K, Limsalakpetch A, Gettayacamin M, Lanar DE, Ware LA, Stewart VA, Heppner DG, Mettens P, Cohen JD, Ballou WR, Fukuda MM.

Infect Immun. 2008 Jan;76(1):229-38. Epub 2007 Oct 22.

15.

Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.

Speake C, Pichugin A, Sahu T, Malkov V, Morrison R, Pei Y, Juompan L, Milman N, Zarling S, Anderson C, Wong-Madden S, Wendler J, Ishizuka A, MacMillen ZW, Garcia V, Kappe SH, Krzych U, Duffy PE.

PLoS One. 2016 Jul 19;11(7):e0159449. doi: 10.1371/journal.pone.0159449. eCollection 2016. Erratum in: PLoS One. 2016 Oct 20;11(10 ):e0165489.

16.

Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens.

Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL, Baldi P, Felgner PL, Doolan DL.

Mol Cell Proteomics. 2011 Sep;10(9):M111.007948. doi: 10.1074/mcp.M111.007948. Epub 2011 May 31.

17.

The march toward malaria vaccines.

Hoffman SL, Vekemans J, Richie TL, Duffy PE.

Vaccine. 2015 Nov 27;33 Suppl 4:D13-23. doi: 10.1016/j.vaccine.2015.07.091. Epub 2015 Aug 29. Review.

PMID:
26324116
18.

Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants.

Voepel N, Boes A, Edgue G, Beiss V, Kapelski S, Reimann A, Schillberg S, Pradel G, Fendel R, Scheuermayer M, Spiegel H, Fischer R.

Biotechnol J. 2014 Nov;9(11):1435-45. doi: 10.1002/biot.201400350. Epub 2014 Oct 10.

PMID:
25200253
19.

Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens.

Noland GS, Jansen P, Vulule JM, Park GS, Ondigo BN, Kazura JW, Moormann AM, John CC.

Acta Trop. 2015 Feb;142:47-56. doi: 10.1016/j.actatropica.2014.10.011. Epub 2014 Oct 24.

20.

Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.

Nguyen TV, Sacci JB Jr, de la Vega P, John CC, James AA, Kang AS.

Malar J. 2009 Oct 23;8:235. doi: 10.1186/1475-2875-8-235.

Supplemental Content

Support Center